trending Market Intelligence /marketintelligence/en/news-insights/trending/V3E_l3q0hED-ildUv-rpEg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Aptevo's treatment for bone marrow cancer receives US FDA's orphan-drug tag

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Aptevo's treatment for bone marrow cancer receives US FDA's orphan-drug tag

The U.S. Food and Drug Administration has granted orphan-drug designation to Aptevo Therapeutics Inc.'s antibody treatment for acute myelogenous leukemia, or AML, a cancer of the blood and bone marrow.

The treatment, APVO436, works by binding to two cell receptors in the immune system, CD123 and CD3, to aid the body in detecting and fighting cancerous cells.

The treatment is being tested in a phase 1/1b clinical trial to test its effectiveness in fighting a group of cancers of the bone marrow, including AML, a rapidly progressing cancer originating from the production of dysfunctional blood cells in the body.

The orphan-drug designation encourages companies to develop cures for rare diseases by offering tax reductions, fee exemptions and a license to be the sole sellers of approved treatments for 7 years.

On Oct. 4, the company discontinued APVO210, its experimental drug for autoimmune diseases, after it failed to meet the desired product profile for commercialization in an early-stage study.